Castleman disease - null regimens

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main Castleman disease page for regimens that include active anticancer treatment.

HHV-8-negative/"Idiopathic" multicentric Castleman disease, all lines of therapy



Study Dates of enrollment Evidence Comparator Comparative Efficacy
van Rhee et al. 2014 (CR016705) 2010-02-09 to 2012-02-03 Randomized Phase 2 (C) Siltuximab Inferior durable tumor and symptomatic response for at least 18 weeks

No active treatment; all patients did receive "best supportive care."


  1. CR016705: van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug;15(9):966-74. Epub 2014 Jul 17. Erratum in: Lancet Oncol. 2014 Sep;15(10):417. link to original article PubMed NCT01024036